Showing results (121-130 of 162) with videos related to
Sort By:
Pageof 17
Breast Cancer Research and Treatment|May 8, 2012
Expression of activated type I receptor tyrosine kinases in early breast cancerMelanie Spears, Hans Christian Pederson, Nicola Lyttle, et al.BMJ Oncology|June 24, 2025
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD dataHelena M Earl, Louise Hiller, Janet A Dunn, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7Aleix Prat, Nadia Solovieff, Fabrice André, et al.Breast Cancer Research and Treatment|June 19, 2010
Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group studyJanine L Mansi, Ann Yellowlees, Julian Lipscombe, et al.Breast Cancer Research and Treatment|March 11, 2011
The p160 ER co-regulators predict outcome in ER negative breast cancerMelanie Spears, Steffi Oesterreich, Ilenia Migliaccio, et al.The Lancet. Oncology|January 19, 2010
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)John M S Bartlett, Alison F Munro, Janet A Dunn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2005
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group studyT R Jeffry Evans, Ann Yellowlees, Elizabeth Foster, et al.Breast Cancer Research : BCR|July 10, 2010
Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapyJohn M S Bartlett, Jeremy Thomas, Douglas T Ross, et al.Health Technology Assessment (Winchester, England)|February 12, 2016
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancerRobert C Stein, Janet A Dunn, John M S Bartlett, et al.Journal of the National Cancer Institute|August 12, 2025
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patientsMatteo Lambertini, Deirdre Allegranza, Ruediger P Laubender, et al.Pageof 17